Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
11.76B | 11.01B | 10.94B | 10.93B | 9.56B | Gross Profit |
6.83B | 7.92B | 7.68B | 7.82B | 6.91B | EBIT |
6.16B | 7.24B | 73.00M | 82.00M | 6.35B | EBITDA |
5.21B | 7.20B | 7.08B | 7.26B | -728.00M | Net Income Common Stockholders |
1.61B | 2.81B | 2.72B | 2.59B | -1.54B |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
10.82B | 6.34B | 5.79B | 9.14B | 6.79B | Total Assets |
234.97B | 231.45B | 226.54B | 238.03B | 224.75B | Total Debt |
58.06B | 50.97B | 46.25B | 46.22B | 39.10B | Net Debt |
47.24B | 44.63B | 40.54B | 41.79B | 37.51B | Total Liabilities |
82.28B | 76.54B | 71.33B | 73.54B | 65.41B | Stockholders Equity |
95.78B | 94.36B | 92.82B | 95.84B | 92.11B |
Cash Flow | Free Cash Flow | |||
5.04B | 3.91B | 378.00M | -1.14B | -546.00M | Operating Cash Flow |
5.21B | 4.02B | 3.10B | 1.74B | 2.58B | Investing Cash Flow |
-3.07B | -2.85B | -4.18B | -1.95B | -2.57B | Financing Cash Flow |
2.38B | -566.00M | -1.93B | 3.63B | 3.61B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
79 Outperform | HK$16.58B | 10.28 | 1.69% | 10.67% | 8.13% | -42.62% | |
61 Neutral | $2.83B | 10.89 | 0.42% | 9.23% | 5.94% | -21.26% | |
$1.26B | ― | -3.12% | 7.61% | ― | ― | ||
$16.47B | 20.40 | 1.94% | 9.84% | ― | ― | ||
$1.55B | ― | -10.34% | 10.17% | ― | ― | ||
$219.12M | ― | -2.65% | ― | ― | ― | ||
€349.22M | ― | -0.98% | 3.47% | ― | ― |
Hang Lung Group Limited announced the successful approval of all proposed resolutions at its annual general meeting held on April 30, 2025. Key resolutions included the approval of audited financial statements, declaration of a final dividend, re-election of directors, re-appointment of KPMG as auditor, and granting of mandates to the board for share buybacks and issuance. These approvals are expected to strengthen the company’s governance and operational capabilities, potentially enhancing its market position and stakeholder confidence.
Hang Lung Group Limited announced the composition of its board of directors, highlighting the roles and functions of its executive, non-executive, and independent non-executive directors. This announcement provides clarity on the leadership structure, potentially impacting the company’s governance and strategic decision-making processes.
Hang Lung Group Limited, a company incorporated in Hong Kong, has announced the appointment of Ms. May Siew Boi TAN as a member of its Nomination and Remuneration Committee effective March 27, 2025. Ms. TAN, who brings extensive experience from her roles at Manulife Financial Corporation and CLP Holdings Limited, is expected to enhance the company’s organizational strategy and governance, potentially impacting its operational effectiveness and stakeholder relations.